ICIs combined with ChT improved clinical outcomes over Beva combined with ChT as first‐line therapy for adenocarcinoma patients without driver gene alterations, especially in patients with PD‐L1 ≥ 1%. The gene discussed is CD274; the disease is adenocarcinoma.